<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00351273</url>
  </required_header>
  <id_info>
    <org_study_id>R21AR053646</org_study_id>
    <secondary_id>R21AR053646</secondary_id>
    <secondary_id>1R21AR053646-01</secondary_id>
    <nct_id>NCT00351273</nct_id>
  </id_info>
  <brief_title>Combination Antibiotic Treatment for Reactive Arthritis Caused by Chlamydia Bacteria</brief_title>
  <official_title>Phase 3 Trial to Assess the Efficacy of Long-term (6 Months) Combination Antibiotics as a Treatment for Chlamydia-induced Reactive Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of South Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of South Florida</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Reactive arthritis, also known as Reiter's syndrome, is a form of arthritis that occurs as a
      reaction to an infection elsewhere in the body. It is characterized by inflammation of the
      joints, tendons, urogenital tract, and eyes. Pain and swelling in the knees, ankles, and feet
      are common. This study will determine the effectiveness of antibiotic therapy in treating
      people with chlamydia-induced reactive arthritis that has lasted for more than 6 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The initial infection that causes reactive arthritis is caused by one of two bacteria:
      Chlamydia trachomatis, which is usually acquired through sexual contact, or Chlamydia
      pneumoniae, which can cause respiratory infections. Most people recover fully from the
      initial flare of arthritis symptoms. However, about 20% of people with reactive arthritis
      experience long-lasting symptoms. In these individuals, the Chlamydia bacteria exist in a
      persistent metabolically active state within the joint tissue, even years after the initial
      exposure. The bacteria produce heat shock proteins (HSPs), which are thought to play a key
      role in the chronic persistent state of Chlamydia and which may stimulate the immune
      inflammatory response seen in reactive arthritis. This indicates the need for antimicrobial
      therapy that can reduce Chlamydia's HSP production and block its metabolism. The purpose of
      this study is to determine the effectiveness of long-term combination antibiotic therapy in
      treating people with chronic reactive arthritis. The study will use two different
      combinations of common antibiotics: doxycycline paired with rifampin and azithromycin paired
      with rifampin.

      This study will entail 6 months of treatment followed by 3 months of follow-up. After
      screening, eligible participants will be randomly assigned to one of three treatment groups:
      rifampin once a day plus doxycycline twice a day; rifampin once a day plus azithromycin once
      a day for 5 days, then twice weekly; or placebo. Study visits will occur at baseline and
      Months 1, 3, 6, and 9. At all visits, participants will undergo an interview, a physical
      examination, and blood collection. They will also complete a questionnaire related to their
      symptoms and functional status. At screening and Month 6, a synovial biopsy may be performed.
      This will involve taking a sample of the tissue that lines the joints.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Investigate Whether a 6 Month Course of Combined Antibiotics Was Effective Treatment.</measure>
    <time_frame>Month 6</time_frame>
    <description>The outcome measure was a composite endpoint. Participants had to meet 4/6 clinical criteria. 17/24 subjects randomized to combination antibiotics did respond to treatment when compared to 3/10 randomized to placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Individual Comparison of 6 &quot;Responder&quot; Criteria in the Combination Antimicrobial Groups Versus the Placebo Group</measure>
    <time_frame>Months 6 and 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Erythrocyte Sedimentation Rate (ESR) and C-reactive Protein (CRP)</measure>
    <time_frame>Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psoriatic Arthritis Response Criteria (PsARC): Swollen Joint Count, Tender Joint Count, Physician and Patient Global Assessment</measure>
    <time_frame>Months 6 and 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Activity Score 44 (DAS44): Ritchie Articular Index (Tender Joint Count), Swollen Joint Count (Out of 44 Joints), ESR, Patient Global Assessment (Visual Analog Scale)</measure>
    <time_frame>Months 6 and 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dactylitis</measure>
    <time_frame>Months 6 and 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Enthesitis (Presence or Absence of Plantar Fasciitis or Achilles Tendonitis)</measure>
    <time_frame>Months 6 and 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Assessment Questionnaire (HAQ)</measure>
    <time_frame>Months 6 and 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With a Complete Response (Resolution of All Symptoms)</measure>
    <time_frame>Months 1, 3, 6 and 9</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Arthritis, Reactive</condition>
  <condition>Reiter Disease</condition>
  <arm_group>
    <arm_group_label>Azithromycin and Rifampin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received Azithromycin and Rifampin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Doxycycline and Rifampin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received Doxycycline and Rifampin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>received placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxycycline and Rifampin</intervention_name>
    <description>doxycycline 100mg daily; rifampin 300mg daily (both for 6 months)</description>
    <arm_group_label>Doxycycline and Rifampin</arm_group_label>
    <other_name>Atridox and Rifadin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin and Rifampin</intervention_name>
    <description>Azithromycin 500mg daily for 5 days and then twice weekly; Rifampin 300mg daily (both for 6 months)</description>
    <arm_group_label>Azithromycin and Rifampin</arm_group_label>
    <other_name>Zithromax and Rifadin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Methylcellulose</description>
    <arm_group_label>received placebo</arm_group_label>
    <other_name>Placebo effect</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meet the following European Spondyloarthropathy Study Group Criteria:

               1. inflammatory spinal pain OR

               2. synovitis AND

               3. one or more of the following:

                    1. positive family history

                    2. urethritis or cervicitis within 1 month prior to onset of arthritis

                    3. buttock pain

                    4. enthesopathy

                    5. sacroiliitis

          -  Disease duration of at least 6 months

          -  Negative pregnancy test at study baseline and willing to use an effective method of
             contraception other than combined oral contraceptives for the duration of the study
             (for women of childbearing age)

        Exclusion Criteria:

          -  Sensitivity or history of allergic reaction to rifampin, doxycycline, or azithromycin

          -  Currently taking any medications that may interact with the study medications,
             specifically rifampin

          -  Liver transaminases greater than or equal to two times the normal level

          -  Significant abnormalities in the complete blood count (CBC)

          -  Pregnant

          -  Current psoriasis

          -  Diagnosis of inflammatory bowel disease

          -  Diagnosis of ankylosing spondylitis

          -  Previous prolonged exposure to antibiotics (more than 2 weeks) as a potential
             treatment for reactive arthritis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John D. Carter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of South Florida</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louisiana State University</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Toronto</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <reference>
    <citation>Carter JD, Valeriano J, Vasey FB. Doxycycline versus doxycycline and rifampin in undifferentiated spondyloarthropathy, with special reference to chlamydia-induced arthritis. A prospective, randomized 9-month comparison. J Rheumatol. 2004 Oct;31(10):1973-80.</citation>
    <PMID>15468362</PMID>
  </reference>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 10, 2006</study_first_submitted>
  <study_first_submitted_qc>July 10, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2006</study_first_posted>
  <results_first_submitted>August 5, 2009</results_first_submitted>
  <results_first_submitted_qc>June 27, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 10, 2016</results_first_posted>
  <last_update_submitted>August 10, 2016</last_update_submitted>
  <last_update_submitted_qc>August 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chlamydia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Chlamydia Infections</mesh_term>
    <mesh_term>Arthritis, Reactive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Doxycycline</mesh_term>
    <mesh_term>Rifampin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Azithromycin &amp; Rifampin</title>
          <description>Participants will receive Azithromycin and Rifampin</description>
        </group>
        <group group_id="P2">
          <title>Doxycycline &amp; Rifampin</title>
          <description>Participants will receive Doxycycline and Rifampin</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Participants will receive placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Azithromycin &amp; Rifampin</title>
          <description>Participants will receive Azithromycin and Rifampin</description>
        </group>
        <group group_id="B2">
          <title>Doxycycline &amp; Rifampin</title>
          <description>Participants will receive Doxycycline and Rifampin</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Participants will receive placebo</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="15"/>
            <count group_id="B4" value="42"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.5" spread="12"/>
                    <measurement group_id="B2" value="43.8" spread="12.3"/>
                    <measurement group_id="B3" value="49" spread="16.3"/>
                    <measurement group_id="B4" value="45.8" spread="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Investigate Whether a 6 Month Course of Combined Antibiotics Was Effective Treatment.</title>
        <description>The outcome measure was a composite endpoint. Participants had to meet 4/6 clinical criteria. 17/24 subjects randomized to combination antibiotics did respond to treatment when compared to 3/10 randomized to placebo.</description>
        <time_frame>Month 6</time_frame>
        <population>Efficacy and safety analyses were performed on an intent to treat(ITT) basis. Subjects who prematurely withdrew or who were lose to follow up for any reason were included in the ITT population and were considered nonresponders.</population>
        <group_list>
          <group group_id="O1">
            <title>Azithromycin &amp; Rifampin</title>
            <description>Participants will receive Azithromycin and Rifampin</description>
          </group>
          <group group_id="O2">
            <title>Doxycycline &amp; Rifampin</title>
            <description>Participants will receive Doxycycline and Rifampin</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants will receive placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Investigate Whether a 6 Month Course of Combined Antibiotics Was Effective Treatment.</title>
          <description>The outcome measure was a composite endpoint. Participants had to meet 4/6 clinical criteria. 17/24 subjects randomized to combination antibiotics did respond to treatment when compared to 3/10 randomized to placebo.</description>
          <population>Efficacy and safety analyses were performed on an intent to treat(ITT) basis. Subjects who prematurely withdrew or who were lose to follow up for any reason were included in the ITT population and were considered nonresponders.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Difference in the percentages of participants with response between all those who received combination therapy vs. placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.01</p_value>
            <method>Fisher Exact</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>40.8</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Individual Comparison of 6 &quot;Responder&quot; Criteria in the Combination Antimicrobial Groups Versus the Placebo Group</title>
        <time_frame>Months 6 and 9</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of Erythrocyte Sedimentation Rate (ESR) and C-reactive Protein (CRP)</title>
        <time_frame>Month 6</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Psoriatic Arthritis Response Criteria (PsARC): Swollen Joint Count, Tender Joint Count, Physician and Patient Global Assessment</title>
        <time_frame>Months 6 and 9</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Activity Score 44 (DAS44): Ritchie Articular Index (Tender Joint Count), Swollen Joint Count (Out of 44 Joints), ESR, Patient Global Assessment (Visual Analog Scale)</title>
        <time_frame>Months 6 and 9</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dactylitis</title>
        <time_frame>Months 6 and 9</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Enthesitis (Presence or Absence of Plantar Fasciitis or Achilles Tendonitis)</title>
        <time_frame>Months 6 and 9</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health Assessment Questionnaire (HAQ)</title>
        <time_frame>Months 6 and 9</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With a Complete Response (Resolution of All Symptoms)</title>
        <time_frame>Months 1, 3, 6 and 9</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Azithromycin &amp; Rifampin</title>
          <description>Participants will receive Azithromycin and Rifampin</description>
        </group>
        <group group_id="E2">
          <title>Doxycycline &amp; Rifampin</title>
          <description>Participants will receive Doxycycline and Rifampin</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Participants will receive placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>John D. Carter, M.D.</name_or_title>
      <organization>University of South Florida</organization>
      <phone>(813) 974-2681</phone>
      <email>jocarter@health.usf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

